July 23, 2017

Johnson & Johnson Introduces Its Cerenovus Neurovascular Business

July 24, 2017—Johnson & Johnson Medical Devices Companies announced the introduction of Cerenovus, its neurovascular business, at the Society of NeuroInterventional Surgery's 14th annual meeting in Colorado Springs, Colorado. Cerenovus will focus on delivering therapies for hemorrhagic and ischemic stroke patients.

Cerenovus’s neurovascular product portfolio was recently expanded with the acquisitions of Pulsar Vascular Inc., which specializes in the endovascular treatment of wide-neck bifurcation aneurysms, and Neuravi, which offers the EmboTrap revascularization platform for the treatment of acute ischemic stroke.

Cerenovus is part of DePuy Synthes Products, Inc. within the Johnson & Johnson Medical Devices Companies segment.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

July 23, 2017

Johnson & Johnson Introduces Its Cerenovus Neurovascular Business

Current Issue

Keep In Touch